ArticleEuropean journal of nuclear medicine and molecular imaging2019
Salvage extended field or involved field nodal irradiation in
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity.Acta oncologica (Stockholm, Sweden) · 2024Pooled it
- Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review.Clinical & experimental metastasis · 2022Pooled it
- Radiotherapy of oligometastatic prostate cancer: a systematic review.Radiation oncology (London, England) · 2021Pooled it
- Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer.Clinical and translational radiation oncology · 2026Article
- Article
- Pattern of recurrence after stereotactic body radiotherapy of nodal lesions: a single-institution analysis.The British journal of radiology · 2024Article
- Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy.Frontiers in oncology · 2024Article
- Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy.Journal of cancer research and clinical oncology · 2023Article
- Mask R-CNN assisted 2.5D object detection pipeline ofScientific reports · 2023Article
- 1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer.Journal of clinical medicine · 2022Article
- Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Article
- [Treatment of primary oligometastatic prostate cancer].Der Urologe. Ausg. A · 2021Review
- Radiotherapy in nodal oligorecurrent prostate cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Review
- Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.Radiation oncology (London, England) · 2021Article
- Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.European journal of nuclear medicine and molecular imaging · 2021Article
- CombiningFrontiers in oncology · 2021Article
- Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- RADIOTHERAPY OF PROSTATE CANCER: PRIMARY RADIOTHERAPY AND RADIOTHERAPY IN DISEASE RELAPSE.Acta clinica Croatica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with
methodsPatients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study. Patients treated with s-IFRT were compared with those treated with s-EFRT. Toxicities and times to failure (TTF) were compared between the two groups.
resultsThe study included 62 patients with positive lymph nodes only who underwent FCH PET/CT for a rising PSA level after radical prostatectomy or radiotherapy. Of these patients, 35 had s-IFRT and 27 had s-EFRT. After a median follow-up of 41.8 months (range 5.9-108.1 months), no differences were observed in acute or late gastrointestinal and genitourinary toxicities of grade 2 or more between the two groups. The 3-year failure rates were 55.3% (95% CI 37.0-70.3%) in the s-IFRT group and 88.3% (95% CI 66.9-96.1%) in the s-EFRT group (p = 0.0094). In multivariate analysis of TTF, an interval of >5 years was significantly correlated with better outcomes (HR = 0.33, 95% CI 0.13-0.86, p = 0.023). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy (HR = 0.38, 95% CI 0.12-1.27, p = 0.116).
conclusionFCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely.
Indexed as
Identifiers
30267117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.